Gyre Therapeutics, Inc.
NASDAQ:GYREBiotechnology
+$0.00 today
- Market cap
- $475.02M
- Beta
- 4.92
- P/E (TTM)
- -88.3
- EPS (TTM)
- -$0.07
Volume 0.47M
Average 0.09M
GYRE Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
Gyre Therapeutics, Inc.NASDAQ: GYRE
Revenue · Q1 FY2026 · quarter ended Mar 2026
Revenue grows, but more slowly than its trailing trend
Q1 FY2026 revenue of $22.52M rose 2.1% year over year, behind the +16.3% change in trailing-twelve-month revenue. Sequentially, it fell 39.5% from the prior quarter. Over 3 fiscal years it compounded at +4.5% a year.
Context
- Revenue increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether revenue reaches the consensus estimate from 2 analysts of $112.63M (-3.4%) for the fiscal year ending Dec 2026, a slowdown from the +10.2% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $22.52M-39.5% QoQ
- Last fiscal yearDec 2025
- $116.59M+10.2% YoY
- LTMMar 2026
- $117.05M+16.3% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +2.1% | -1.0% | -3.1 pp |
| 1 year | +10.2% | -3.4% | -13.6 pp |
| 3-year CAGR | +4.5% | +57.0% | +52.5 pp |
| 5-year CAGR | +22.6% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Revenue history
USD · from the income statement
- Latest · FY2025
- 116.59M USD
- Year-over-year change
- +10.2%
- 4-year CAGR
- +99.6%
| Period | Period end | Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 116.59M | +10.2% |
| FY2024 | 2024-12-31 | 105.76M | -6.8% |
| FY2023 | 2023-12-31 | 113.45M | +10.9% |
| FY2022 | 2022-12-31 | 102.29M | +1294.0% |
| FY2021 | 2021-12-31 | 7.34M | — |
Revenue vs competitors
How GYRE compares with its peers on the latest reported figures
- Peers report in different currencies, so revenue is compared through growth and rates rather than absolute size.
- Its year-over-year change of +16.3% is the highest of 2, against a peer median of -35.6%.
- Over three fiscal years its annual growth of +4.5% compares with a peer median of -34.7%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | $117.05M USD | +16.3% | +4.5% | |
| LTM Mar 2026 | $7.49M USD | -35.6% | -34.7% | |
AGMBAgomAb Therapeutics N.V. American Depositary Shares | FY2024 | €0 EUR | — | — |
| LTM Mar 2026 | $0 USD | — | — | |
| LTM Mar 2026 | $0 USD | — | — | |
| Peer median (excluding GYRE) | — | -35.6% | -34.7% | |
Competitors are the stored peer set for GYRE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 7.34M | 102.29M | 113.45M | 105.76M | 116.59M |
| Cost of Revenue | 7.67M | 4.79M | 4.64M | 3.88M | 5.42M |
| Gross Profit | (332K) | 97.5M | 108.81M | 101.87M | 111.17M |
| Gross Margin | -4.5% | 95.3% | 95.9% | 96.3% | 95.4% |
| Research & Development | 64.57M | 16.69M | 13.78M | 12.02M | 13.7M |
| Selling, General & Admin | 18.82M | 71.61M | 75.82M | 73.62M | 85.98M |
| Operating Expenses | 83.39M | 88.29M | 176.04M | 85.71M | 99.68M |
| Depreciation & Amortization | 290K | 1.13M | 1.11M | 1.59M | 2.52M |
| EBITDA | (87.64M) | 10.54M | 20.33M | 17.82M | 16.96M |
| EBITDA Margin | -1194.4% | 10.3% | 17.9% | 16.8% | 14.5% |
| Operating Income | (83.73M) | 9.2M | (67.23M) | 16.16M | 11.49M |
| Operating Margin | -1141.0% | 9.0% | -59.3% | 15.3% | 9.9% |
| Interest Income | 39K | 726K | 1.04M | 1.55M | 1.75M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (4.21M) | 209K | (9.74M) | 7.06M | 2.95M |
| Income Before Tax | (87.93M) | 9.41M | (76.97M) | 23.22M | 14.44M |
| Pre-Tax Margin | -1198.3% | 9.2% | -67.8% | 22.0% | 12.4% |
| Income Tax Expense | 0 | 5.1M | 8.52M | 5.32M | 4.56M |
| Net Income | (87.93M) | 2.3M | (92.93M) | 12.09M | 5.03M |
| Net Margin | -1198.3% | 2.3% | -81.9% | 11.4% | 4.3% |
| EPS (Basic) | (2.87) | 0.03 | (1.41) | 0.14 | 0.06 |
| EPS (Diluted) | (2.87) | 0.03 | (1.41) | 0.05 | 0.02 |
| Weighted Avg Shares | 30.64M | 76.74M | 65.83M | 85.09M | 89.34M |
| Weighted Avg Shares (Diluted) | 30.64M | 75.69M | 65.83M | 102.29M | 103.18M |
Gyre Therapeutics, Inc.
NASDAQ:GYRE
Intrinsic Alpha fair value
Locked
Current Price
$4.34
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.